Key facts
- It has raised $18.0M; the latest was Later Stage VC ($18.0M) in Apr 2025.
- Notable investors include Mediino Partners, Sui Generis Partners, TAIL Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for DeepQure
- ·The full record, as it builds
Funding rounds
No funding rounds for DeepQure are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About DeepQure
Manufacturer of medical devices intended to treat high blood pressure, particularly in patients with resistant hypertension. The company's product offers a wide range of features like the switch to release RF energy on the electrode guide an emergency release system to release the electrode guide in case of malfunction safely, an activation switch protective cover, adjustment of the size of the electrode guide, and electrode guide that conducts RF energy, enabling healthcare providers to offer a non-drug treatment option that could significantly reduce the risks associated with uncontrolled hypertension.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2019
- Employees
- 13
- Website
- deepqure.com/
- Ownership
- Privately Held (backing)
DeepQure doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in DeepQure shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on DeepQure in its N-PORT filings yet. We sweep new filings monthly.